News | December 14, 2024
Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio
The trademark rights for these brands will be transferred to Lupin by March next year.
The trademark rights for these brands will be transferred to Lupin by March next year.
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
This is recommended for in-ovo vaccination of 18 to 19-day-old embryonated chicken eggs and one-day old chickens to protect against the virulent Marek’s disease
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus
Subscribe To Our Newsletter & Stay Updated
